Prostate Cancer Drug Darolutamide Linked to Far Less Cognitive Decline Than Rival
A phase II trial found darolutamide caused significantly less cognitive decline than enzalutamide in advanced prostate cancer patients.
Summary
A phase II clinical trial presented at the 2026 ASCO annual meeting found that men with advanced prostate cancer treated with darolutamide experienced significantly less cognitive decline than those treated with enzalutamide. Over 24 weeks, patients on enzalutamide showed a 36% drop in cognitive performance versus just 16% for darolutamide users. Researchers believe the difference stems from darolutamide's limited ability to cross the blood-brain barrier, meaning it targets fewer androgen receptors in the brain. While no patients were diagnosed with dementia, real-world cognitive impacts like memory loss, falls, and impaired functioning were highlighted as serious concerns. Experts say this finding could meaningfully guide treatment decisions to help preserve cognitive health in this vulnerable population.
Detailed Summary
Cognitive decline is a serious but often underappreciated side effect of treatments for advanced prostate cancer. A new phase II trial called ARACOG, presented at the 2026 American Society of Clinical Oncology annual meeting, directly compared two of the most widely used androgen receptor pathway inhibitors — darolutamide and enzalutamide — specifically for their effects on brain function. The findings offer a meaningful signal for clinicians and patients choosing between these therapies.
The core result was striking: patients on enzalutamide experienced a 36.1% decline in their maximally changed cognitive domain score over 24 weeks, compared to just 15.8% for those on darolutamide. That difference was statistically significant (P=0.009) and was measured using the Cambridge Neuropsychological Test Automated Battery, which evaluates executive function, visual memory, attention, and working memory across 111 men with a median age of 71.
The likely explanation lies in brain pharmacology. Darolutamide has limited ability to cross the blood-brain barrier, meaning it exerts less influence on androgen receptors within the central nervous system. Enzalutamide penetrates the brain more readily, which may disrupt neurological pathways involved in cognition. This structural difference between the two molecules appears to translate into a real functional outcome for patients.
ASCO President Eric Small emphasized that cognitive loss in this population is not merely a test score — it manifests as memory problems, falls, job loss, and loss of independence. While no patients in either group were diagnosed with dementia during the trial, the measurable changes are clinically meaningful at the individual level.
Important caveats remain. The trial was open-label and relatively small at 111 participants, and the lead researcher cautioned against treating this as a definitive mandate for one drug over the other. Treatment decisions must still account for individual tumor biology, disease stage, and overall health status. Nevertheless, for patients and oncologists weighing cognitive preservation, this trial provides actionable evidence.
Key Findings
- Darolutamide caused 15.8% cognitive decline vs 36.1% for enzalutamide over 24 weeks in prostate cancer patients.
- The difference is likely due to darolutamide's limited ability to cross the blood-brain barrier.
- Cognitive impacts included memory loss, falls, and impaired daily functioning in real-world contexts.
- No patients in either group were diagnosed with dementia during up to 48 weeks of follow-up.
- Findings may help guide drug selection to preserve cognitive health in advanced prostate cancer treatment.
Methodology
This is a news report from MedPage Today summarizing results from the ARACOG phase II prospective open-label clinical trial presented at ASCO 2026. The trial enrolled 111 men and used the validated CANTAB neuropsychological battery to assess cognitive outcomes. Evidence quality is moderate given the open-label design and relatively small sample size.
Study Limitations
The trial was open-label, introducing potential bias, and the sample size of 111 men limits generalizability. No participants were diagnosed with dementia, so the long-term clinical significance of the observed cognitive changes remains unclear. Full peer-reviewed publication of the trial data has not yet been confirmed from the article text.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.